伏格列波糖对肝脏毒性的临床观察  

Clinical observation on effect of voglibose on liver toxicity

作　　者：林华容[1] 陆静明[1] 陈少明[1] 

机构地区：[1]潮州市中心医院综合科,521000

出　　处：《中国实用医药》2014年第21期28-29,共2页China Practical Medicine

摘　　要：目的探讨伏格列波糖对糖尿病患者肝脏毒性的影响。方法 2型糖尿病患者56例,分为肝功能正常组(32例)和肝功能轻度异常组(24例),均给予两组患者服用12周的伏格列波糖进行治疗,观察比较两组患者的肝功能指标和血糖变化情况。结果经过治疗后肝功能正常组和肝功能轻度异常组患者的血糖均下降,但两组患者在治疗前后的肝功能指标(丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、直接胆红素(DBIL)、总胆汁酸(TA))的变化不明显,差异无统计学意义(P>0.05)。结论伏格列波糖可以改善糖尿病患者的高血糖症状,在治疗过程中并未产生肝脏毒性。Objective To study effect of voglibose on liver toxicity of patients with diabetes. Methods Divided 56 patients with type 2 diabetes into liver function normal group（32 cases） and mild abnormal liver function group（24 cases）, two groups of patients were treated by of voglibose for 12 weeks, liver function index and blood sugar changes of two groups were compared. Results After treatment, the blood glucose of two groups decreased, but the liver function indexes（alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, total bile acid） changes of two groups before and after treatment were not obvious, there was no statistically significant difference（P〉0.05）. Conclusion Voglibose can improve the symptoms of diabetes patients with high blood sugar and does not produce liver toxicity in the process of treatment.

关 键 词：伏格列波糖 肝脏毒性 临床观察 

分 类 号：R587.1[医药卫生—内分泌]